Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A Q909* |
| Therapy | Niraparib |
| Indication/Tumor Type | skin melanoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A Q909* | skin melanoma | predicted - sensitive | Niraparib | Case Reports/Case Series | Actionable | In a Phase II clinical trial, Zejula (niraparib) therapy demonstrated activity in melanoma patients harboring mutations in HRR pathway genes, resulting in a partial response (PR) rate of 14% (2/14) and disease control rate (DCR) of 64% (9/14), with stable disease in 7 patients and a median progression-free survival of 16 weeks; response rate was 20% (2/10, 2 PR) and DCR was 70% (7/10) in patients with non-uveal melanoma, including a PR in a cutaneous melanoma patient harboring ARID1A Q909* (PMID: 40373259). | 40373259 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40373259) | Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | Full reference... |